2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Dopamine Receptor
  5. Dopamine Receptor Isoform
  6. Dopamine Receptor Inhibitor

Dopamine Receptor Inhibitor

Dopamine Receptor Inhibitors (66):

Cat. No. Product Name Effect Purity
  • HY-A0081
    Fluphenazine dihydrochloride
    		Inhibitor 99.89%
    Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
  • HY-B0532A
    Trifluoperazine dihydrochloride
    		Inhibitor 99.98%
    Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis.
  • HY-N0300
    Tetrahydropalmatine
    		Inhibitor 99.72%
    Tetrahydropalmatine possesses analgesic effects. Tetrahydropalmatine acts through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats.
  • HY-B1110
    Nomifensine
    		Inhibitor 98.93%
    Nomifensine is a norepinephrine-dopamine reuptake inhibitor, increases the amount of synaptic norepinephrine and dopamine available to receptors by blocking the dopamine and norepinephrine reuptake transporters.
  • HY-113468A
    3-O-Methyldopa
    		Inhibitor 98.87%
    3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine.
  • HY-U00096
    Ansofaxine hydrochloride
    		Inhibitor 99.72%
    Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor; inhibits serotonin, dopamine and norepinephrine reuptake with IC50 values of 723, 491 and 763 nM, respectively.
  • HY-B1110A
    Nomifensine maleate
    		Inhibitor 98.79%
    Nomifensine maleate is a selective inhibitor of dopamine uptake, used in adult attention deficit disorder.
  • HY-108510
    Rimcazole dihydrochloride
    		Inhibitor 99.96%
    Rimcazole (BW 234U) dihydrochloride is a carbazole derivative that acts in part as a sigma (σ) receptor antagonist. Rimcazole dihydrochloride also binds with moderate affinity to the dopamine transporter and inhibit dopamine uptake. Rimcazole dihydrochloride can reduce locomotor activity and sensitization. Rimcazole dihydrochloride also can be used for the research of cancer.
  • HY-113468AS
    3-O-Methyldopa-d3
    		Inhibitor 99.34%
    3-O-Methyldopa-d3 is deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].
  • HY-12751A
    Trimethobenzamide hydrochloride
    		Inhibitor 99.92%
    Trimethobenzamide hydrochloride is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.
  • HY-B0411A
    Domperidone monomaleate
    		Inhibitor 99.76%
    Domperidone (R33812) monomaleate is an orally active and selective dopamine-2 receptor antagonist. Domperidone monomaleate acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine.
  • HY-119468
    Medifoxamine
    		Inhibitor 99.72%
    Medifoxamine is a monoamine re-uptake inhibiting antidepressive agent which preferentially inhibits dopamine reuptake.
  • HY-B1017
    Molindone hydrochloride
    		Inhibitor 99.78%
    Molindone hydrochloride (EN-1733A) is a therapeutic antipsychotic, used in the treatment of schizophrenia, works by blocking the effects of dopamine in the brain, leading to diminished psychoses.
  • HY-100968
    GBR 12783 dihydrochloride
    		Inhibitor 99.14%
    GBR 12783 dihydrochloride is a specific, potent and selective dopamine uptake inhibitor that inhibits the [3H]dopamine uptake by rat and mice striatal synaptosomes with IC50s of 1.8 nM and 1.2 nM, respectively. GBR 12783 dihydrochloride can improve memory performance and increase hippocampal acetylcholine release in rats.
  • HY-106587A
    Octoclothepin maleate salt
    		Inhibitor 99.14%
    Octoclothepin maleate salt, an orally active neuroleptic agent, is a dual SR-2A and D2DR inhibitor. Octoclothepin maleate salt reveals an intensive central depressant action in a series of observational and instrumental procedures in rodents.
  • HY-W016388
    9-Fluorenol
    		Inhibitor 99.87%
    9-Fluorenol (9-Hydroxyfluorene; compound 3) is a dopamine (DAT) inhibitor with IC50 value of 9 μM. 9-Fluorenol is a major metabolite of compound developed as a wake promoting agent. 9-Fluorenol shows wake promotion activity in vivo.
  • HY-N0300A
    Tetrahydropalmatine hydrochloride
    		Inhibitor 99.91%
    Tetrahydropalmatine (DL-Tetrahydropalmatine) hydrochloride possesses analgesic effects. Tetrahydropalmatine hydrochloride acts through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats.
  • HY-W008610
    GBR 12783
    		Inhibitor
    GBR 12783 is a specific, potent and selective dopamine uptake inhibitor that inhibits the [3H]dopamine uptake by rat and mice striatal synaptosomes with IC50s of 1.8 nM and 1.2 nM, respectively. GBR 12783 can improve memory performance and increase hippocampal acetylcholine release in rats.
  • HY-100143
    Pentiapine
    		Inhibitor 99.95%
    Pentiapine (CGS 10746) is a dopamine release inhibitor without binding to synaptic dopamine receptor sites.
  • HY-W401531S
    (R)-3-O-Methyldopa-d3
    		Inhibitor
    (R)-3-O-Methyldopa-d3 is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].